Transparency Market Research has published a new market report titled, “Global Plasma Protein Therapeutics Market: (Product Type – Coagulation Factors, Immunoglobulins, Albumin, C1-esterase Inhibitors, Alpha-1 Antitrypsin, and Others; Application: Hemophilia, Primary Immunodeficiency Disorder, Idiopathic Thrombocytopenic Purpura, Secondary Immunodeficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, and Others) – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2016–2024.” According to the report, the global plasma protein therapeutics market was valued at US$ 18.5 Bn in 2015 and is projected to reach US$ 31.8 Bn by 2024.
Download Free exclusive Sample of this report:
Plasma protein are blood-derived medicines used in wide therapeutic areas. Life threatening diseases such as chronic lymphocytic leukemia, multiple myeloma, congenital AIDS, and hemophilia are treated with plasma-derived proteins. Market related factors such as growing use of immunoglobulins in primary immunodeficiency, and wide opportunities for human albumin in treatment of burns, shock and blood loss and also as a drug formulation agent, vaccine ingredient, sealant in surgeries, and coating for medical devices and equipment. Other factors such as growing demand for plasma protein therapeutics owing to increasing development in new indications, additional application in existing indications, innovative solutions for safe and efficient plasma collection, better access to medicines in emerging markets, and new plasma-derived therapies drive the plasma protein therapeutics market.
Geographically, the global plasma protein therapeutics market has been segmented into the following regions: North America, Europe, Asia Pacific, Latin America, and Rest of the World. North America accounted for the largest share of 40.7% of the global plasma protein therapeutics market in 2015. Intravenous immunoglobulin (IVIG) was the largest segment of the market primarily due to increasing usage in new indications, new researches, and increasing geriatric population. According to the Immune Deficiency Foundation, currently around 55,000 people in the U.S. with antibody deficiency receive PIDD treatment through IVIG. The plasma protein therapeutics market in North America will be further fueled by the increasing usage of immunoglobulins and C1 esterase inhibitors segment during the forecast period.
Europe was the second largest market for plasma protein therapeutics in 2015. This is attributed to high rate of plasma donation and growing demand for plasma protein in increasing number of indications. The intravenous immunoglobulin segment in Europe is expected to expand at an impressive CAGR during the forecast period due to increase in the number of patients with bleeding disorders and growing number of chronic inflammatory demyelinating polyneuropathy (CIPD) cases. Europe has experienced a surge in the amount of plasma collected and processed, which nearly doubled in the last decade. The immunoglobulin market continues to grow due to the increase in the number of clinical indications for IG. Germany was the leading market for plasma protein therapeutics in Europe, accounting for one-third share in 2015, followed by France, the U.K., Italy, and Spain. In terms of volume, Sweden was the largest market for plasma protein, followed by France, Spain, Italy, Switzerland, the U.K. and Germany.
Asia Pacific is projected to be the most attractive market for plasma protein therapeutics during the forecast period. The market in the region is anticipated to expand at the highest CAGR of 8.1% from 2016 to 2024. This is due to strong demand for immunoglobulin and albumin, improving health care facilities, increasing health care expenditure, and growing public awareness. China dominated the plasma protein therapeutics market in Asia Pacific. China imports 56% of its albumin supply to alleviate shortage and to decrease the demand-supply gap. Hence, albumin is projected to be the fastest growing segment in Asia Pacific. Other factors such as economic development in emerging economies such as India and China, where increase in health care expenditure and growing public awareness about immunodeficiency disorders would help the region to prevail as the most attractive market. Growing demand for IVIG in replacing absent antibodies in immune failure and treating immune deficiency, and other unmet medical needs is likely to propel the market in Asia Pacific.
Latin America is one of the largest economic regions of the future. Strong sales and market growth are expected over the medium term due to new marketing approvals for immunoglobulin and improved diagnosis rate of immunodeficiency. Companies are strengthening their regional presence in Latin America due to increasing product demand and growth opportunity in the region. Brazil is the leading market for plasma protein therapeutics in Latin America, followed by Mexico.
Key players in the global plasma protein therapeutics market are Baxter International, Biotest, CSL Behring, Grifols, S.A., Kedrion, Octapharma USA, Inc., Shire plc, and China Biologics. Baxalta (acquired by Shire plc), Grifols, and CSL Behring are likely to average 7% plasma sales growth between them over the next five years.